Abstract
Genetic leukoencephalopathies (gLEs) are a highly heterogeneous group of rare genetic disorders. The spectrum of gLEs varies among patients of different ages. Distinct from the relatively more abundant studies of gLEs in children, only a few studies that explore the spectrum of adult gLEs have been published, and it should be noted that the majority of these excluded certain gLEs. Thus, to date, no large study has been designed and conducted to characterize the genetic and phenotypic spectra of gLEs in adult patients.
We recruited a consecutive series of 309 adult patients clinically suspected of gLEs from Beijing Tiantan Hospital between January 2014 and December 2021. Whole-exome sequencing, mitochondrial DNA sequencing and repeat analysis of NOTCH2NLC, FMR1, DMPK and ZNF9 were performed for patients. We describe the genetic and phenotypic spectra of the set of patients with a genetically confirmed diagnosis and summarize their clinical and radiological characteristics.
A total of 201 patients (65%) were genetically diagnosed, while 108 patients (35%) remained undiagnosed. The most frequent diseases were leukoencephalopathies related to NOTCH3 (25%), NOTCH2NLC (19%), ABCD1 (9%), CSF1R (7%) and HTRA1 (5%). Based on a previously proposed pathological classification, the gLEs in our cohort were divided into leukovasculopathies (35%), leuko-axonopathies (31%), myelin disorders (21%), microgliopathies (7%) and astrocytopathies (6%). Patients with NOTCH3 mutations accounted for 70% of the leukovasculopathies, followed by HTRA1 (13%) and COL4A1/2 (9%). The leuko-axonopathies contained the richest variety of associated genes, of which NOTCH2NLC comprised 62%. Among myelin disorders, demyelinating leukoencephalopathies (61%)—mainly adrenoleukodystrophy and Krabbe disease—accounted for the majority, while hypomyelinating leukoencephalopathies (2%) were rare. CSF1R was the only mutated gene detected in microgliopathy patients. Leukoencephalopathy with vanishing white matter disease due to mutations in EIF2B2-5 accounted for half of the astrocytopathies.
We characterized the genetic and phenotypic spectra of adult gLEs in a large Chinese cohort. The most frequently mutated genes were NOTCH3, NOTCH2NLC, ABCD1, CSF1R and HTRA1.
Keywords: genetic leukoencephalopathy, leukodystrophy, white matter lesion, genetic spectrum, pathological classification
Wu et al. describe the clinical and radiological features of genetic leukoencephalopathies in a large cohort of 309 adults, and find that the most frequently mutated genes are NOTCH3 (25%), NOTCH2NLC (19%), ABCD1 (9%), CSF1R (7%) and HTRA1 (5%).
Introduction
Genetic leukoencephalopathies (gLEs) are a highly heterogeneous group of rare disorders that predominantly affect CNS white matter.1 They can occur at any age. Affected individuals have a wide spectrum of clinical presentations, including cognitive impairment, psychiatric symptoms, developmental retardation, stroke, ataxia, pyramidal signs, movement disorders, seizures, peripheral neuropathy and extraneurological symptoms.2 The imaging patterns can vary according to the disease and its time course.3
Several large-scale studies have been conducted to describe the genetic spectrum of gLEs in childhood.4–7 Metachromatic leukodystrophy (MLD) is the most common diagnosis and accounts for 8.2–25.3% of childhood gLEs.4–6 Other main causes include adrenoleukodystrophy (ALD), Krabbe disease, mitochondrial disease, vanishing white matter disease (VWMD), Pelizaeus–Merzbacher disease and mucopolysaccharidoses.4–7 Adult patients present with an obviously distinct disease spectrum compared to children. In a European study, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) was the most frequent diagnosis, comprising 33% of adult gLEs.8
Adult gLEs are considered rare and difficult to diagnose. Therefore, only a few studies on the spectrum of adult gLEs have been published to date.8–11 The results vary among these studies because of different inclusion and exclusion criteria, diagnostic methods and populations. In a cohort of 154 patients, CADASIL, VWMD, ALD and COL4A1-related disorders were the most common diagnoses.8 In another study excluding classical leukodystrophies, VWMD ranked first place in adult gLEs, followed by CADASIL and adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).9 In recent years, the detection of an increasing number of novel genes has contributed to a constantly changing genetic spectrum for gLEs.12–16 In 2019, GGC expansion in NOTCH2NLC was found associated with neuronal intranuclear inclusion disease (NIID), and this exceeded CADASIL as the most frequently diagnosed cause of adult gLEs in a recent Japanese cohort.10,16
The clinical heterogeneity of gLEs reflects the contribution of diverse cellular pathologies. Genetic leukoencephalopathies can be caused by defects in any white matter structural components, including myelin, astrocytes, microglia, axons and blood vessels.17 Genetic leukoencephalopathies with similar cellular pathology can share common clinical and radiological manifestations; therefore, knowledge of which cell types are primarily involved can be helpful in understanding clinical manifestations.17–19
In the present study, we describe the genetic and phenotypic spectra of adult gLEs based on a large Chinese cohort and summarize the clinical and radiological characteristics of the various pathological types of gLEs.
Materials and methods
Patients
A consecutive series of 309 adult patients clinically suspected of gLEs were recruited from the Department of Neurology, Beijing Tiantan Hospital, between January 2014 and December 2021. The inclusion criteria for adult patients clinically suspected of gLEs in our study were: (i) the presence of a progressive neurological syndrome and white matter lesions of the cerebrum/spinal cord on MRI or CT scan; (ii) acquired causes, including cerebrovascular diseases secondary to non-genetic causes (such as atherosclerosis and cardioembolism), toxic injuries, infection, drug-induced changes, inflammation, and neoplastic diseases were excluded; and (iii) at least 16 years old at the time of referral to our centre.
Clinical and imaging data were collected at the first visit to our clinic and were reviewed by at least two senior neurologists and a neuroradiologist. Written informed consent was obtained from all participants, and this study was approved by the Ethics Committees of Beijing Tiantan Hospital (ID of the ethics approval: KY2020-105-02).
Genetic testing
Whole-exome sequencing
Whole-exome sequencing (WES) was conducted for all 309 patients. Genomic DNA was extracted from peripheral blood. WES was performed based on All Exon Kits (V6; Agilent) and then sequenced using the Illumina HiSeq2000 platform. Sequences were aligned to hg19 using the Burrows–Wheeler Aligner.20 Single nucleotide variants and small insertions/deletions (indels) were identified using the Genome Analysis Toolkit and annotated using ANNOVAR.21,22 Copy number variants were analysed by ExomeDepth.23 Variants were filtered using the following criteria: (i) hypothesized inheritance pattern coherent with family history; (ii) allele frequency lower than 1% among recessive disease-associated genes and 0.1% among dominant disease-associated genes in each of the following databases: 1000 Genomes Project, ExAC and gnomAD; (iii) predicted deleterious effect on protein function; and (iv) canonical variants putatively altering splice sites. Predicted deleterious effects were analysed using SIFT, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and MutationTaster (https://www.mutationtaster.org/), and the effects of variants on splicing were analysed using SpliceAI (https://spliceailookup.broadinstitute.org/).
All samples underwent a two-step analysis: in the first step, variants in genes previously reported as associated with gLEs were considered (listed in Supplementary Table 1).24 In the second step, all heterozygous variants with an allele frequency <0.01%—as well as homozygous and potentially compound heterozygous variants—were considered.
All variants were classified according to the standards of the American College of Medical Genetics criteria.25 Cases were considered to have a genetically confirmed diagnosis if variants were classified as pathogenic or likely pathogenic. Cases with a variant of unknown significance but compatible segregation analysis and specific clinical and imaging findings highly suggestive of a given disease were also considered genetically diagnosed.
Analysis of repeat expansions
Trinucleotide repeat expansions of NOTCH2NLC were screened in 41 patients suspected of NIID. These cases were clinically diagnosed based on characteristic clinical symptoms, imaging features (e.g. high0intensity signal in the corticomedullary junction on diffusion-weighted imaging of brain MRI) and pathological findings (e.g. eosinophilic hyaline intranuclear inclusions in the skin biopsy).26 Repeat-primed polymerase chain reaction (RP-PCR) and fluorescence amplicon length analysis-PCR (AL-PCR) were used to assess the number of GGC repeats in the NOTCH2NLC gene as reported previously.27 As the cases with FMR1 premutation show the symptoms and intranuclear inclusions as NIID, we analysed the CGG repeat length of FMR1 in these patients to screen fragile X-associated tremor/ataxia syndrome.26,28
Three cases with prominent myotonia and muscle weakness were suspected of myotonic dystrophy and were screened for repeat expansions of DMPK and ZNF9.29,30
Mitochondrial DNA sequencing
Mitochondrial DNA sequencing was performed on 12 patients clinically suspected of having mitochondrial diseases.31,32 These patients had multiple-system involvement (e.g. myopathy, peripheral neuropathy, optic neuropathy, sensorineural hearing loss, diabetes, cardiac abnormality, gastrointestinal, renal or hepatic involvement) and lesions involving the cortex, basal ganglia or brainstem on MRI or CT scan.
Classification system
The pathological classification used in the present study was based on a previous report.17 All genetic leukoencephalopathies were classified based on pathological changes and primary involvement of white matter components.17 According to this classification system, genetic leukoencephalopathies can be classified into five groups, including: (i) myelin disorders, in which oligodendrocytes and myelin are primarily or predominantly affected; (ii) astrocytopathies owing to defects in astrocyte-specific gene products or in which astrocyte dysfunctions play a major pathogenetic role; (iii) leuko-axonopathies secondary to neuronal or axonal defects; (iv) microgliopathies owing to defects in microglia-specific gene products; and (v) leukovasculopathies owing to vascular pathology. Myelin disorders can be subdivided into hypomyelinating leukoencephalopathies, demyelinating leukoencephalopathies and leukoencephalopathies with myelin vacuolization.
Data availability
The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary material.
Results
A total of 201 (65%) of the 309 individuals suspected of gLEs were genetically diagnosed, while 108 patients (35%) remained undiagnosed in our cohort. Among the 201 patients with a genetically confirmed diagnosis, 156 patients (50%) were diagnosed based on the WES data, 42 patients (14%) were diagnosed based on repeat analysis of NOTCH2NLC (13%) and DMPK (1%), while three patients (1%) were diagnosed based on mitochondrial DNA sequencing.
The most frequently mutated genes were NOTCH3 (25%), NOTCH2NLC (19%), ABCD1 (9%), CSF1R (7%) and HTRA1 (5%) (Fig. 1A). Based on pathological classification, the gLEs of our cohort were divided into leukovasculopathies (35%), leuko-axonopathies (31%), myelin disorders (21%), microgliopathies (7%) and astrocytopathies (6%) (Fig. 1B). The most helpful and discriminating clinical and imaging features related to specific gLEs are summarized in Tables 1 and 2 and Supplementary Table 2.
Table 1.
Clinical features of genetic cerebral small vessel disease | |
---|---|
Ischaemic stroke or TIA | CADASIL, CADASIL2, PADMAL |
Haemorrhagic stroke | COL4A1/2-related disorders, CADASIL |
Migraine | CADASIL |
Spondylosis deformans | CADASIL2 |
Paroxysmal muscle spasm | HANAC |
Neuropathic pain | Fabry disease |
Angiokeratoma | Fabry disease |
Renal involvement | COL4A1/2-related disorders, Fabry disease, RVCL-S |
Eye involvement | COL4A1/2-related disorders, RVCL-S |
Imaging features of genetic cerebral small vessel disease | |
Anterior temporal lobe signal abnormality | CADASIL, CADASIL2 |
External capsule signal abnormality | CADASIL, CADASIL2 |
Lacunar infarctions | CADASIL, CADASIL2 |
Cerebral microbleeds | CAA, COL4A1/2-related disorders, CADASIL, CADASIL2 |
Recurrent brainstem infarctions | PADMAL |
Pseudotumor sign | RVCL-S |
CAA = cerebral amyloid angiopathy; HANAC = hereditary angiopathy with nephropathy, aneurysms, and muscle cramps; PADMAL = pontine autosomal dominant microangiopathy and leukoencephalopathy; RVCL-S = autosomal dominant retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations; TIA = transient ischaemic attacks.
Table 2.
Clinical characteristics of hereditary non-vascular leukoencephalopathy | |
---|---|
Psychiatric symptoms | ALD, CblC disease, NIID, AARS2-L, ALSP, VWMD |
Cognitive impairment | ALD, CblC disease, NIID, AARS2-L, ALSP, VWMD |
Early prominent ataxia | CTX, Alexander’s disease, Pol-III-related disorders, GHS, ALD, LBSL, ALSP, VWMD |
Palatal myoclonus | Alexander’s disease |
Peripheral neuropathy | ALD, Krabbe disease, CTX, CMT-X, CblC disease, MTHFR deficiency, NIID, LBSL, mitochondrial disease, HSP |
Autonomic symptoms | ADLD, NIID |
Myopathy | DM1, LGMDR23, mitochondrial disease, AARS2-L, NIID |
Rapid deterioration following head trauma | ALD, VWMD |
Optic nerve atrophy | ALD, LBSL, AARS2-L, mitochondrial disease, VWMD, DM1 |
Cataract | CTX, DM1 |
Oligodontia | Pol-III-related disorders |
Adrenocortical insufficiency | ALD |
Premature ovarian failure | VWMD, AARS2-L |
Hypogonadotrophic hypogonadism | GHS, Pol-III-related disorders |
Tendon xanthoma | CTX |
Imaging characteristics of hereditary non-vascular leukoencephalopathy | |
Corpus callosum involvement | ALSP, VWMD, AARS2-L, HSP (SPG11, SPG15, SPG7), ADLD, NIID |
Abnormal signal along pyramidal tract | Krabbe disease, Pol-III-related disorders |
Spinal cord and brainstem involvement | Alexander’s disease, LBSL |
Cerebellar dentate nucleus | CTX, ALD |
Cerebellar vermis | NIID |
Middle cerebellar peduncles | NIID, LKPAT, ALD, LBSL, VWMD |
Cystic degeneration | VWMD |
Punctate calcification | ALSP, ALD |
Contrast enhancement | ALD |
Deep white matter diffusion dots | ALSP, AARS2-L, LBSL |
High signals along the corticomedullary junction on DWI | NIID |
Transient and reversible white matter lesions | CMT-X |
AARS2-L = AARS2-related leukodystrophy; ADLD = adult-onset autosomal dominant leukodystrophy; CblC = methylmalonic aciduria and homocystinuria cblC type; CMT-X = X-linked Charcot–Marie–Tooth; CTX = cerebrotendinous xanthomatosis; DM1 = myotonic dystrophy type1; DWI = diffusion weighted imaging; GHS = Gordon Holmes syndrome; HSP = hereditary spastic paraplegia; LBSL = leukoencephalopathy with brainstem and spinal cord involvement with elevated lactate; LGMDR23 = autosomal recessive limb-girdle muscular dystrophy-23; LKPAT = leukoencephalopathy with ataxia; MTHFR deficiency = methylenetetrahydrofolate reductase deficiency; SPG = spastic paraplegia.
Leukovasculopathies
The genetic spectrum of leukovasculopathies included NOTCH3 (70%), HTRA1 (13%), COL4A1/2 (9%), APP (4%), TREX1 (3%) and GLA (1%).
CADASIL
A total of 50 CADASIL patients were identified. The average age at onset was 41.8 ± 10.7 (mean ± SD) years. Cognitive impairment (72%), ischaemic cerebrovascular disease (56%), psychiatric symptoms (46%) and migraine (24%) were common symptoms. Intracranial haemorrhage was rare (10%). Neuroimaging data were available for 42 CADASIL patients. White matter involvement of the bilateral external capsules and anterior temporal lobes (Fig. 2A) was observed in 83% and 64% of the patients, respectively. Lacunar infarctions (79%) and microbleeds (57%) were also common imaging findings. Thirty-four mutations were identified in the NOTCH3 gene, including nine novel mutations (Supplementary Tables 3 and 4).
CADASIL2
Heterozygous HTRA1 mutations are associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 2 (CADASIL2).15 Nine probands and two affected siblings carrying heterozygous HTRA1 mutations were diagnosed with CADASIL2. Biallelic mutations in HTRA1 were not found in our cohort. The average age at onset was 41.1 ± 2.7 years. Common neurological symptoms included cognitive impairment (100%), psychiatric symptoms (82%), gait disturbance (73%) and ischaemic stroke (64%). Three patients had spondylosis deformans (Fig. 2B and C). Alopecia was noted in one patient. Neuroimaging data were available for nine patients: all had moderate-to-severe leukoencephalopathy with involvement of bilateral external capsules (100%) and anterior temporal lobes (22%). Lacunar infarctions were observed in all nine patients and microbleeds were observed in six patients. Nine missense mutations in HTRA1 were identified, including six novel mutations (Supplementary Table 5).
COL4A1/2-related disorders
Six patients presented with COL4A1/2-related disorders. The average age at onset was 45.8 ± 11.1 years. Intracranial haemorrhage was found in 2 patients (Fig. 2D) and recurrent brainstem infarctions were found in one patient with pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL, Fig. 2E and F). Two patients who were previously diagnosed with hereditary angiopathy with nephropathy, aneurysm and muscle cramps (HANAC) syndrome had muscle cramps. Intracranial aneurysm was detected in one of the patients with HANAC. Extraneurological symptoms affected the eyes (67%), kidneys (33%) and heart (33%). We identified a heterozygous c.*34G>T mutation in the 3′ untranslated region of the COL4A1 gene in the patient with PADMAL, three other mutations in the coding region of COL4A1 and two mutations in COL4A2 (Supplementary Table 6).
Hereditary cerebral amyloid angiopathy
Three probands from three different families had the same heterozygous mutation c.2059A>C (p.K687Q) in APP. All three patients developed cognitive impairment in their 40s. Multiple cortical and subcortical microbleeds were observed in two patients.
Retinal vasculopathy with cerebral leukodystrophy and systemic manifestations
Two patients had heterozygous TREX1 mutations: c.811_812dupA (p.D272Rfs*6) or c.748_758del (p.T250Pfs*8). Both patients presented with retinal vasculopathy and hemiplegia in adulthood. Renal failure was detected in one patient and seizures were detected in the other patient. Brain imaging of both patients showed enhanced lesions with a mass effect and surrounding oedema on MRI (Fig. 2G) and punctate calcifications beyond the lesion by CT scan (Fig. 2H).
Fabry disease
We identified a male patient with the GLA mutation c.672T>G (p.N224K). The patient presented with burning pain of the feet and reduced sweating in early life. He was referred to our hospital for recurrent ischaemic attacks at the age of 25. Angiokeratoma and proteinuria were detected.
Myelin disorders
The myelin disorder cases in our cohort could be subdivided into hypomyelinating leukoencephalopathies (2%), demyelinating leukoencephalopathies (61%) and leukoencephalopathies with myelin vacuolization (37%). The genetic causes of this group included GJC2, ABCD1, GALC, CYP27A1, GJB1, PAH, MMACHC, MTHFR, GCDH and LMNB1. The most common mutated gene was ABCD1 (46%).
Hypomyelinating leukoencephalopathies
Pelizaeus–Merzbacher-like disease
We identified novel compound heterozygous GJC2 mutations in a female with Pelizaeus–Merzbacher-like disease (Supplementary Table 7). She had psychomotor retardation and nystagmus in early life and developed progressive spasticity and ataxia at the age of 20. A brain CT scan showed symmetric hypointensities in the periventricular white matter.
Demyelinating leukoencephalopathies
Adrenoleukodystrophy
A total of 19 male patients were identified (Supplementary Table 8). According to clinical and imaging manifestations, they were classified into childhood cerebral ALD (CCALD, 1/19), adolescent cerebral ALD (AdolCALD, 2/19), adult cerebral ALD (ACALD, 6/19), adrenomyeloneuropathy (AMN, 8/19) and spinocerebellar variant ALD (2/19). Seven patients (37%) had adrenocortical insufficiency. Nineteen mutations were found, including six novel mutations (Supplementary Table 8).
In nine patients with cerebral ALD, cognitive impairment (100%), psychiatric disorders (89%), pyramidal signs (78%), ataxia (56%), sphincter dysfunction (44%) and seizures (44%) were common neurological symptoms. Three patients deteriorated after head trauma. Brain MRI was available for five patients. Three patients had white matter changes with occipitoparietal predominance and two had frontal predominance (Fig. 3A and B). Diffusion-weighted imaging (DWI) hyperintensities and Gd enhancement in the outer layer of lesions were observed in five and two patients, respectively (Fig. 3C). A CT scan showed punctate calcification in one patient (Fig. 3D).
All patients with AMN or spinocerebellar variants developed symptoms in adulthood. Spastic paraplegia (8/8) was the most frequent symptom in AMN, followed by sphincter dysfunction (6/8), peripheral neuropathy (3/8), deep sensory disturbance (2/8), ataxia (2/8) and impotence (1/8). Both patients diagnosed with spinocerebellar variants presented with cerebellar ataxia, dysarthria and pyramidal signs. Symmetrical T2-weighted hyperintensities in the cerebellar dentate nucleus were characteristic imaging findings of the spinocerebellar variant (Fig. 3E).
Krabbe disease
Four patients were diagnosed with Krabbe disease (Supplementary Table 7). Three patients presented with spastic paraplegia/hemiplegia and another patient presented with progressive left upper limb wasting and weakness. Corticospinal tract hyperintensities on T2-weighted images were observed in two patients presenting with spastic paraplegia/hemiplegia (Fig. 3F and G).
Cerebrotendinous xanthomatosis
Two patients with cerebrotendinous xanthomatosis (CTX) developed cerebellar ataxia in early life, followed by mental retardation, dysarthria, spastic paraplegia, peripheral neuropathy and cataracts (Supplementary Table 7). One of them had sensorineural deafness and chronic diarrhoea. Tendon xanthomata was found in the other patient. T2-weighted hyperintensities in the bilateral cerebellar dentate nucleus were found in both patients (Fig. 3H).
Leukoencephalopathies with myelin vacuolization
X-linked Charcot–Marie–Tooth
Three male patients carried hemizygous mutations in GJB1 (Supplementary Table 7). All of the patients presented with slowly progressive distal muscle weakness and atrophy. Sensorineural hearing loss was noted in one patient. Nerve conduction studies in all patients showed slow motor conduction velocities and low-amplitude compound muscle action potentials. Brain MRI in two patients showed transient and reversible white matter lesions with a predominance in the parietal region, which were hyperintensities on DWI and hypointensities on apparent diffusion coefficient imaging (Fig. 3I and J).
Disorders of amino acid and organic acid metabolism
Four male patients with phenylketonuria (PKU) developed mental retardation, light pigmentation of skin and a musty odour in early life (Supplementary Table 7). Their brain MRIs showed diffuse white matter lesions in parallel with the lateral ventricles (Fig. 3K).
Four patients with MMACHC mutations and two with MTHFR mutations shared some similar symptoms, including spastic paraplegia and peripheral neuropathy (Supplementary Table 7). However, patients with MMACHC mutations tended to present with cognitive impairment and psychiatric symptoms as their initial manifestations.
One male patient born to consanguineous parents carried homozygous mutations in GCDH (Supplementary Table 7). He presented with severe paroxysmal headache and mild cognitive impairment in his 20s. Diffuse white matter lesions were detected in bilateral periventricular areas and the centrum semiovale.
Adult-onset autosomal dominant leukodystrophy
We identified LMNB1 gene duplication in a male patient. He presented with spastic paraparesis, parkinsonism, dysarthria, chronic constipation and insomnia at the age of 59. Brain MRI showed extensive T2-weighted hyperintensities in the subcortical and deep white matter with relative sparing of the periventricular rim (Fig. 3L). Ventricular enlargement and thinning of the corpus callosum were also noted.
Leuko-axonopathies
The genetic spectrum of leuko-axonopathies included NOTCH2NLC, AARS2, DARS2, Mt DNA, SPG11, ZFYVE26, SPG7, POLR3A, RNF216, HEXB, IDS and DMPK. The most frequently mutated gene was NOTCH2NLC (62%).
Neuronal intranuclear inclusion disease
In our cohort, 39 patients were diagnosed with NIID (Supplementary Table 9). The number of GGC repeat expansions in NOTCH2NLC was between 87 and 159. Twenty-five (64%) patients were female. The mean age of onset was 54.9 ± 9.4 years. Cognitive impairment (92%), autonomic dysfunction (79%), episodic neurological events (64%), tremor (54%), psychiatric symptoms (49%) and headache (46%) were the most common symptoms. Episodic neurological events included disturbances of consciousness, encephalitic episodes, stroke-like episodes, epilepsy, paroxysmal headache, dizziness, nausea and vomiting.
Brain MRI was available for 35 patients. Dilated lateral ventricles (97%), high signals along the corticomedullary junction on DWI (Fig. 4A, 86%) and diffuse white matter lesions (80%) were the characteristic signs. T2 hyperintensities in the cerebellar vermis (Fig. 4B) and middle peduncle were present in 40% and 20% of the patients, respectively.
AARS2-related leukodystrophy
We identified four patients with biallelic mutations in AARS2 (Supplementary Table 10). Three patients developed cognitive impairment, psychiatric disorders and motor dysfunction in adulthood. Another male patient suffered delayed motor development in infancy and developed cognitive impairment and psychiatric symptoms at the age of 25. The only female patient had premature ovarian failure at the age of 35. All of the patients shared similar imaging findings, including periventricular white matter lesions, corpus callosum atrophy, mild ventricular enlargement and punctate DWI hyperintensities within white matter lesions (Fig. 4C).
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation
We identified a patient with compound heterozygous mutations in DARS2 (Supplementary Table 10). The patient presented with delayed motor development in infancy and was admitted to our hospital for slowly progressive ataxia and weakness in the lower limbs. Brain and spinal cord MRI showed T2 hyperintensities in the periventricular white matter, medullary pyramids, medial lemniscus, dorsal columns and lateral corticospinal tracts of the spinal cord (Fig. 4D). Diffusion-weighted imaging revealed symmetric hyperintensities in the medullary pyramids, middle and inferior cerebellar peduncles, cerebellar dentate nucleus and cerebellar vermis. In the supratentorial area, punctate hyperintensities on DWI were distributed in periventricular white matter lesions (Supplementary Figure 1).
Mitochondrial DNA mutations
We identified three patients with mitochondrial DNA mutations (Supplementary Table 10). These patients presented with variable combinations of cognitive decline, psychiatric symptoms, extrapyramidal symptoms, ataxia, ophthalmoplegia, sensorineural deafness, epilepsy, myopathy and peripheral neuropathy. Abnormal signals in the basal ganglia were observed in all three patients. Diffuse white matter lesions were found in one patient (Fig. 4E) and asymmetrical periventricular white matter lesions were found in the other two patients.
Pol-III-related disorders
We identified two patients with compound heterozygous POLR3A mutations (Supplementary Table 10). They presented with progressive ataxia and spastic paraplegia since childhood. Oligodontia and intellectual disability were noted in one patient. Both had poor pubertal development. T2 hyperintensities in pyramidal tracts were detected in both patients (Fig. 4F).
Hereditary spastic paraplegia
We found white matter lesions in eight patients with hereditary spastic paraplegia (SPG), including five patients with SPG11, two with SPG15 and one with SPG7 (Supplementary Table 10). All of the patients except the one with SPG7 developed spastic paraplegia in adolescence. Periventricular white matter lesions accompanied by corpus callosum atrophy were the distinct imaging manifestations (Fig. 4G).
Myotonic dystrophy type 1
Three male patients were diagnosed with myotonic dystrophy type 1 (Supplementary Table 10). All of them presented with myotonia, weakness and muscle wasting in early adulthood or adolescence. Mild cognitive impairment, sensorineural deafness, alopecia and cataracts were also common symptoms. Brain MRI showed diffuse white matter lesions with the involvement of temporal lobes in one patient (Fig. 4H). Patchy periventricular or subcortical white matter lesions were observed in the other two patients.
Sandhoff disease, Gordon Holmes syndrome and mucopolysaccharidosis type II
We identified compound heterozygous HEXB mutations in a patient with Sandhoff disease (Supplementary Table 10). She presented with lower motor neuron syndrome at the age of 23. Brain MRI showed marked cerebellar atrophy (Fig. 4I).
Novel homozygous mutations in RNF216 were detected in a male patient diagnosed with Gordon Holmes syndrome (GHS; Supplementary Table 10). The patient had a history of hypogonadotropic hypogonadism and developed ataxia, dysarthria and cognitive impairment at the age of 26. Brain MRI revealed extensive white matter lesions and cerebellar atrophy (Fig. 4J and K).
We identified a novel hemizygous IDS mutation in a male patient with mucopolysaccharidosis type II (MPS II; Supplementary Table 10). He suffered recurrent upper respiratory tract infections in childhood and had abdominal protuberance, macrocephaly, skeletal deformities and amblyopia. Brain MRI showed enlarged perivascular spaces that were clustered, resembling bunches of grapes (Fig. 4L).
Microgliopathies
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
There were 14 patients diagnosed with ALSP (Supplementary Table 11). The average age of onset was 36.9 ± 9.1 years. Pyramidal signs (86%), cognitive impairment (71%), ataxia (57%), psychiatric symptoms (43%) and parkinsonism (14%) were the common symptoms (Supplementary Table 11). Brain MRI data were available for eight patients and revealed periventricular white matter lesions (Fig. 5A), dilated lateral ventricles and thinning of the corpus callosum. Seven patients (88%) had characteristic punctate DWI hyperintensities within white matter lesions (Fig. 5B). All 11 mutations were located at exons 17–21, which encode the tyrosine kinase domain of the CSF1R protein (Supplementary Table 11).
Astrocytopathies
The genetic spectrum of astrocytopathies comprised GFAP, EIF2B2-5, CLCN2 and LAMA2. VWMD caused by EIF2B2-5 mutations was the most common disease (50%).
Vanishing white matter disease
We identified six patients with biallelic mutations in EIF2B2-5 (Supplementary Table 12). The age of onset ranged from infancy to 41 years. Cognitive impairment (100%), ataxia (83%), pyramidal signs (67%) and psychiatric symptoms (50%) were common neurological symptoms. Deterioration following head trauma was noted in two patients. Three of four female patients had premature ovarian failure. Diffuse white matter lesions with cystic degeneration were characteristic imaging findings (Fig. 5C and D). Thinning of the corpus callosum and T2 hyperintensities in the middle cerebellar peduncles were also observed.
Alexander’s disease
Three patients with Alexander’s disease were identified (Supplementary Table 12). The onset age of the patients ranged from infancy to adulthood. Progressive ataxia (3/3) and pyramidal signs (3/3) were the most frequent symptoms, followed by bulbar signs (2/3), bladder dysfunction (2/3), palatal myoclonus (1/3) and cognitive impairment (1/3). Brain MRI of all three patients showed prominent atrophy of the medulla and spinal cord (tadpole sign; Fig. 5E). Symmetric patchy or diffuse white matter lesions were located in the periventricular areas and centrum semiovale.
Autosomal recessive limb-girdle muscular dystrophy-23
We identified two male patients with compound heterozygous mutations in LAMA2 (Supplementary Table 12). Both presented with seizures and one had progressive weakness of distal lower extremities. Diffuse white matter lesions with involvement of the anterior temporal lobes were detected in both patients (Fig. 5F).
Leukoencephalopathy with ataxia
We identified a male patient with a novel homozygous mutation in CLCN2 (Supplementary Table 12). The patient suffered severe recurrent headache at the age of 41. A brain MRI showed T2 hyperintensities in the middle cerebellar peduncles and posterior limbs of the internal capsule (Fig. 5G and H).
Discussion
It has been established that gLEs represent a diverse group of diseases characterized by rarity, high heterogeneity and challenging diagnosis.33 To the best of our knowledge, this is the largest cohort to date to explore the genetic and phenotypic spectra of adult gLEs. In our study, approximately two-thirds of genetic causes were NOTCH3, NOTCH2NLC, ABCD1, CSF1R and HTRA1. NOTCH3 and NOTCH2NLC far exceeded other genes and accounted for approximately half of the genetic causes. A recent Japanese study reported that NOTCH2NLC and NOTCH3 were the most frequently mutated genes in adult gLEs and comprised 82% of all diagnosed patients.10 Of note, GGC expansions in NOTCH2NLC, rather than NOTCH3 mutations, were the most frequent cause in the Japanese study.10 In European studies, NOTCH3 and EIF2B mutations were the most common genetic causes of adult gLEs, accounting for 33% and 13% of diagnosed patients, respectively.8,9ABCD1 and CSF1R mutations were also frequently detected in adult gLEs, while HTRA1 mutations were rarely reported in previous cohort studies.8–10,34
According to the pathological classification proposed by van der Knaap and Bugiani,17 leukovasculopathies in our cohort represent the largest proportion, followed by leuko-axonopathies, myelin disorders, microgliopathies and lastly astrocytopathies. Note that some disorders that are not considered primary genetic leukoencephalopathies but which are considered neurogenetic disorders with white matter abnormalities (e.g. X-linked Charcot–Marie–Tooth, CMT-X) were included in the present study. CMT-X is caused by mutations in GJB1 coding for connexin-32 (Cx32).35 Cx32 is a gap-junction channel-forming protein expressed in Schwann cells and oligodendrocytes, the myelinating glia of the peripheral and CNS, respectively.36 Although CMT-X has been described as a peripheral neuropathy, CNS manifestations (e.g. acute episodic neurological dysfunction) have been reported in CMT-X.36 Transient and reversible white matter lesions in bilateral deep white matter (as well as the corpus callosum) have been reported as characteristic imaging features of CMT-X patients with episodic neurological dysfunction.37 The CNS manifestations in CMT-X may be associated with loss of oligodendrocyte–oligodendrocyte and oligodendrocyte–astrocyte junctional coupling mediated by Cx32, while oligodendrocyte–oligodendrocyte coupling is likely to be the more important for the transient CNS dysfunction.38 Accordingly, CMT-X is recognized as a genetic leukoencephalopathy and is classified among myelin disorders owing to the primary involvement of oligodendrocytes.1,17
The leukovasculopathies were the largest part of our gLE cohort. CADASIL due to NOTCH3 mutations was the most frequent diagnosis and accounted for 70% of the leukovasculopathies and 25% of the patients with a genetically confirmed diagnosis. This proportion is slightly lower than reported in previous studies, in which CADASIL comprised 33–39% of all diagnosed gLE patients.8,10 Although HTRA1 mutations were rarely detected in previous cohort studies, they were the second most frequent genetic cause of leukovasculopathies in our cohort.8–10,34,39 Interestingly, all the patients with HTRA1-related cerebral small vessel disease (CSVD) carried a heterozygous mutation, and no biallelic mutations in HTRA1 were identified in our study, indicating that among Chinese patients heterozygous HTRA1-related CADASIL2 is more frequent than cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). COL4A1/2-related disorders were another common leukovasculopathy in our cohort; these were previously reported to constitute 7% of all diagnosed gLE patients in a European study.8 In our patients, early-onset cognitive impairment and stroke, combined with lacunar infarctions and microbleeds on MRI, are common characteristics of leukovasculopathies except for retinal vasculopathy with cerebral leukodystrophy and systemic manifestations (RVCL-S), which invariably mimics tumours.40 Moreover, intracranial haemorrhage and multiple microbleeds are suggestive of COL4A1/2-related disorders or cerebral amyloid angiopathy.41 Systematic involvement, including the eyes, kidney, skin and heart, is prominent in COL4A1/2-related disorders, Fabry disease and RVCL-S.41 Spondylosis deformans is a distinct extraneurological symptom of HTRA1-related CSVD, with a frequency of 100% in CARASIL and 60% in CADASIL2.42
The leuko-axonopathies constituted a variety of diseases, with NIID being the most frequent of these disorders. Given that CGG repeat expansions in NOTCH2NLC were only reported to be associated with NIID in 2019, to date, few studies have been conducted to explore the proportion of NIID among adult gLEs.10,16 In agreement with a Japanese study,10 our study found that NIID is a common genetic cause of adult gLEs in East Asia. Notably, a recent study screened NOTCH2NLC expansion in a European cohort of adult-onset leukoencephalopathy and did not identify any patients with GGC repeat expansion in NOTCH2NLC.43 In the future, more studies are needed to profile the incidence of NIID in different populations. The phenotype of NIID is variable, while the imaging appearance is specific.26,44 High-intensity signals in the corticomedullary junction on DWI were reported in 95.9% of NIID cases in a previous study.26
SPG11 mutations, which are the most common cause of complex hereditary spastic paraplegia,45 were the second genetic cause of leuko-axonopathies in our cohort. In a previous study, two patients carrying SPG11 mutations were identified in 97 patients genetically diagnosed with gLEs, which is consistent with our results (5/201).8 White matter abnormalities and corpus callosum thinning on MRI are the imaging features of SPG11.45AARS2 was another frequent genetic cause of leuko-axonopathies in our study but was rarely identified in previous cohorts.9,10,34,39 For AARS2 mutation-related leukodystrophy, premature ovarian failure and punctate hyperintensities on DWI are the characteristic clinical and imaging signs.46 Previous studies have also reported punctate hyperintensities on DWI for patients with leukoencephalopathy with brainstem and spinal cord involvement and elevated cerebrospinal fluid lactate (LBSL) or ALSP.46–48 In our experience, the punctate diffusion restriction changes in the periventricular white matter appear similar among LBSL, ALSP and AARS2-related leukodystrophy (Supplementary Figure 2). It is difficult to distinguish these three diseases based solely on punctate diffusion restriction in the periventricular white matter. However, symmetric T2-weighted and DWI hyperintensities in the brainstem and cerebellum—which are distinctive imaging sign for patients with LBSL but rare in patients with ALSP or AARS2-related leukodystrophy—can be used to informatively distinguish LBSL from AARS2-related leukodystrophy and from ALSP.46–49
In myelin disorders, demyelinating leukodystrophies, including ALD and Krabbe disease, constitute the majority, while hypomyelinating leukodystrophies are rare. Note that MLD is the most common type of childhood leukoencephalopathy but was not found in the patients comprising our cohort.4–6 ALD comprised 3.6–9.2% of childhood gLEs and 11.3% of adult gLEs in previous studies.4–8 Although ALD is a frequent diagnosis in both child and adult patients with gLEs, the clinical phenotypes are different between the two groups.50 Child patients frequently present with cerebral ALD and progress rapidly, while most adult patients present with adrenomyeloneuropathy (AMN) and progress slowly.50,51 In our cohort, we found that AMN was the most common subtype and accounted for 42% of ALD cases. Approximately one-third of ALD patients presented with adult cerebral ALD in our cohort, suggesting that this subtype is not rare in adult patients with ALD. Patients with cerebral ALD could deteriorate rapidly after head trauma,52,53 as observed in our cohort: three cerebral ALD patients had a rapid deterioration and progression of neuroinflammation following head trauma. The spinocerebellar variant is a rare phenotype and accounts for 1–2% of ALD.54 The actual proportion of spinocerebellar variants may be higher in Asia: we found that it was 10.5% in our cohort and was previously reported as 8.4% in a Japanese study.55
Microglia comprise a set of neurological phenotypes linked to mutations in CSF1R, DAP12 and TYROBP/TREM2, USP18, IRF8 and NRROS.56 In our study, CSF1R was the only mutated gene detected in microgliopathy patients and comprised 7% of the genetically diagnosed patients. In a European cohort of 48 patients, CSF1R mutations accounted for 10% of idiopathic adult-onset leukodystrophies.57 Nevertheless, the proportion of CSF1R-related disorders was lower in the other European study, accounting for 2% of adult gLEs.8 ALSP is characterized by dementia, psychiatric changes and motor decline.58 The MRI appearance is consistent among patients, including deep white matter lesions, enlargement of lateral ventricles, atrophy of the corpus callosum, punctate hyperintensities on DWI and calcifications.58
Although the astrocytopathies were the rarest group in our study, VWMD in the astrocytopathies is known as one of the most common gLEs in both children and adult patients.6,8,9 The proportion of VWMD in gLEs ranged from 2% to 13% in paediatric studies4–7 and reached 13% in a European study on adult gLEs.8 In another European study excluding classical leukodystrophies, VWMD was the most frequent diagnosis in adult patients with gLEs and comprised 19% of diagnosed patients.9 In our cohort, the frequency of VWMD (3%) was lower than that of previous European studies but similar to the findings of a Japanese study (1 patient with VWMD among 28 patients genetically diagnosed with gLE).10 In clinical practice, typical cystic degeneration of the white matter and premature ovarian failure easily distinguish VWMD from other genetic leukoencephalopathies.59
In conclusion, we here described the genetic and phenotypic spectra of adult gLEs in a large Chinese cohort. In our cohort, NOTCH3, NOTCH2NLC, ABCD1, CSF1R and HTRA1 were the most frequently mutated genes. It is worth noting that the GGC expansion in NOTCH2NLC, which might have been underestimated in previous studies, is a common genetic cause of adult gLEs in China. Our study should be beneficial for advancing clinical practice, genetic counselling and disease classification for adults with gLEs.
Supplementary Material
Contributor Information
Chujun Wu, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Mengwen Wang, Department of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, 350005 Fuzhou, China.
Xingao Wang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Wei Li, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Shaowu Li, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Bin Chen, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Songtao Niu, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Hongfei Tai, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Hua Pan, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Zaiqiang Zhang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China; China National Clinical Research Centre for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, 100070 Beijing, China.
Funding
No funding was received towards this work.
Competing interests
The authors report no competing interests.
Supplementary material
Supplementary material is available at Brain online.
References
- 1. Vanderver A, Prust M, Tonduti D, et al. Case definition and classification of leukodystrophies and leukoencephalopathies. Mol Genet Metab. 2015;114:494–500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Köhler W, Curiel J, Vanderver A. Adulthood leukodystrophies. Nat Rev Neurol. 2018;14:94–105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Schiffmann R, van der Knaap MS. Invited article: An MRI-based approach to the diagnosis of white matter disorders. Neurology. 2009;72:750–759. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Bonkowsky JL, Nelson C, Kingston JL, Filloux FM, Mundorff MB, Srivastava R. The burden of inherited leukodystrophies in children. Neurology. 2010;75:718–725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Stellitano LA, Winstone AM, van der Knaap MS, Verity CM. Leukodystrophies and genetic leukoencephalopathies in childhood: A national epidemiological study. Dev Med Child Neurol. 2016;58:680–689. [DOI] [PubMed] [Google Scholar]
- 6. Alfadhel M, Almuqbil M, Al Mutairi F, et al. The leukodystrophy spectrum in Saudi Arabia: Epidemiological, clinical, radiological, and genetic data. Front Pediatr. 2021;9:633385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Knuutinen OA, Oikarainen JH, Suo-Palosaari MH, et al. Epidemiological, clinical, and genetic characteristics of paediatric genetic white matter disorders in Northern Finland. Dev Med Child Neurol. 2021;63:1066–1074. [DOI] [PubMed] [Google Scholar]
- 8. Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, et al. Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. Brain. 2015;138:284–292. [DOI] [PubMed] [Google Scholar]
- 9. Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. Brain. 2017;140:1204–1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Okubo M, Doi H, Fukai R, et al. GGC Repeat expansion of NOTCH2NLC in adult patients with leukoencephalopathy. Ann Neurol. 2019;86:962–968. [DOI] [PubMed] [Google Scholar]
- 11. Kunii M, Doi H, Ishii Y, et al. Genetic analysis of adult leukoencephalopathy patients using a custom-designed gene panel. Clin Genet. 2018;94:232–238. [DOI] [PubMed] [Google Scholar]
- 12. Depienne C, Bugiani M, Dupuits C, et al. Brain white matter oedema due to ClC-2 chloride channel deficiency: An observational analytical study. Lancet Neurol. 2013;12:659–668. [DOI] [PubMed] [Google Scholar]
- 13. Margolin DH, Kousi M, Chan YM, et al. Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination. N Engl J Med. 2013;368:1992–2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Dallabona C, Diodato D, Kevelam SH, et al. Novel (ovario) leukodystrophy related to AARS2 mutations. Neurology. 2014;82:2063–2071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Verdura E, Hervé D, Scharrer E, et al. Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease. Brain. 2015;138:2347–2358. [DOI] [PubMed] [Google Scholar]
- 16. Sone J, Mitsuhashi S, Fujita A, et al. Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nat Genet. 2019;51:1215–1221. [DOI] [PubMed] [Google Scholar]
- 17. van der Knaap MS, Bugiani M. Leukodystrophies: A proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134:351–382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Yamamoto Y, Craggs L, Baumann M, Kalimo H, Kalaria RN. Review: Molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol Appl Neurobiol. 2011;37:94–113. [DOI] [PubMed] [Google Scholar]
- 19. Berdowski WM, Sanderson LE, van Ham TJ. The multicellular interplay of microglia in health and disease: Lessons from leukodystrophy. Dis Model Mech. 2021;14:dmm048925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Li H. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics. 2014;30:2843–2851. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–1303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Plagnol V, Curtis J, Epstein M, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics. 2012;28:2747–2754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Shukla A, Kaur P, Narayanan DL, do Rosario MC, Kadavigere R, Girisha KM. Genetic disorders with central nervous system white matter abnormalities: An update. Clin Genet. 2021;99:119–132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17:405–424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Sone J, Mori K, Inagaki T, et al. Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain. 2016;139:3170–3186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Deng J, Gu M, Miao Y, et al. Long-read sequencing identified repeat expansions in the 5'UTR of the NOTCH2NLC gene from Chinese patients with neuronal intranuclear inclusion disease. J Med Genet. 2019;56:758–764. [DOI] [PubMed] [Google Scholar]
- 28. Lyon E, Laver T, Yu P, et al. A simple, high-throughput assay for Fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. J Mol Diagn. 2010;12:505–511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Butterfield RJ, Imburgia C, Mayne K, et al. High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis. Mol Genet Genomic Med. 2021;9:e1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Catalli C, Morgante A, Iraci R, Rinaldi F, Botta A, Novelli G. Validation of sensitivity and specificity of tetraplet-primed PCR (TP-PCR) in the molecular diagnosis of myotonic dystrophy type 2 (DM2). J Mol Diagn. 2010;12:601–606. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Fang F, Liu Z, Fang H, et al. The clinical and genetic characteristics in children with mitochondrial disease in China. Sci China Life Sci. 2017;60:746–757. [DOI] [PubMed] [Google Scholar]
- 32. Ng YS, Bindoff LA, Gorman GS, et al. Mitochondrial disease in adults: Recent advances and future promise. Lancet Neurol. 2021;20:573–584. [DOI] [PubMed] [Google Scholar]
- 33. van der Knaap MS, Schiffmann R, Mochel F, Wolf NI. Diagnosis, prognosis, and treatment of leukodystrophies. Lancet Neurol. 2019;18:962–972. [DOI] [PubMed] [Google Scholar]
- 34. Xie JJ, Ni W, Wei Q, et al. New clinical characteristics and novel pathogenic variants of patients with hereditary leukodystrophies. CNS Neurosci Ther. 2020;26:567–575. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Kleopa KA, Scherer SS. Molecular genetics of X-linked Charcot–Marie–Tooth disease. Neuromolecular Med. 2006;8:107–122. [DOI] [PubMed] [Google Scholar]
- 36. Abrams CK, Freidin M. GJB1-associated X-linked Charcot–Marie–Tooth disease, a disorder affecting the central and peripheral nervous systems. Cell Tissue Res. 2015;360:659–673. [DOI] [PubMed] [Google Scholar]
- 37. Tian D, Zhao Y, Zhu R, Li Q, Liu X. Systematic review of CMTX1 patients with episodic neurological dysfunction. Ann Clin Transl Neurol. 2021;8:213–223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Abrams CK, Goman M, Wong S, et al. Loss of coupling distinguishes GJB1 mutations associated with CNS manifestations of CMT1X from those without CNS manifestations. Sci Rep. 2017;7:40166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Vanderver A, Simons C, Helman G, et al. Whole exome sequencing in patients with white matter abnormalities. Ann Neurol. 2016;79:1031–1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Stam AH, Kothari PH, Shaikh A, et al. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain. 2016;139:2909–2922. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Sondergaard CB, Nielsen JE, Hansen CK, Christensen H. Hereditary cerebral small vessel disease and stroke. Clin Neurol Neurosurg. 2017;155:45–57. [DOI] [PubMed] [Google Scholar]
- 42. Uemura M, Nozaki H, Kato T, et al. HTRA1-related cerebral small vessel disease: A review of the literature. Front Neurol. 2020;11:545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Yau WY, Sullivan R, Chen Z, et al. GGC repeat expansion in NOTCH2NLC is rare in European leukoencephalopathy. Ann Neurol. 2020;88:641–642. [DOI] [PubMed] [Google Scholar]
- 44. Fan Y, Xu Y, Shi C. NOTCH2NLC-related disorders: The widening spectrum and genotype-phenotype correlation. J Med Genet. 2022;59:1–9. [DOI] [PubMed] [Google Scholar]
- 45. Kara E, Tucci A, Manzoni C, et al. Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain. 2016;139:1904–1918. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Lakshmanan R, Adams ME, Lynch DS, et al. Redefining the phenotype of ALSP and AARS2 mutation-related leukodystrophy. Neurol Genet. 2017;3:e135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Yelam A, Nagarajan E, Chuquilin M, Govindarajan R. Leucoencephalopathy with brain stem and spinal cord involvement and lactate elevation: A novel mutation in the DARS2 gene. BMJ Case Rep. 2019;12:bcr-2018–227755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Werner R, Daum E, Felber S, Wöhrle JC. Leukoencephalopathy with brain stem and spinal cord involvement and not always lactate elevation. Clin Neuroradiol. 2018;28:451–453. [DOI] [PubMed] [Google Scholar]
- 49. Kassem H, Wafaie A, Abdelfattah S, Farid T. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL): Assessment of the involved white matter tracts by MRI. Eur J Radiol. 2014;83:191–196. [DOI] [PubMed] [Google Scholar]
- 50. Mao C, Li J, Huang X, et al. Typical and atypical phenotype and neuroimaging of X-linked adrenoleukodystrophy in a Chinese cohort. Neurolo Sci. 2022;43:3255–3263. [DOI] [PubMed] [Google Scholar]
- 51. Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): Clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Raymond GV, Seidman R, Monteith TS, et al. Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci. 2010;290:70–74. [DOI] [PubMed] [Google Scholar]
- 53. Bouquet F, Dehais C, Sanson M, Lubetzki C, Louapre C. Dramatic worsening of adult-onset X-linked adrenoleukodystrophy after head trauma. Neurology. 2015;85:1991–1993. [DOI] [PubMed] [Google Scholar]
- 54. Kemp S, Pujol A, Waterham HR, et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: Role in diagnosis and clinical correlations. Hum Mutat. 2001;18:499–515. [DOI] [PubMed] [Google Scholar]
- 55. Suzuki Y, Takemoto Y, Shimozawa N, et al. Natural history of X-linked adrenoleukodystrophy in Japan. Brain Dev. 2005;27:353–357. [DOI] [PubMed] [Google Scholar]
- 56. Smith C, McColl BW, Patir A, et al. Biallelic mutations in NRROS cause an early onset lethal microgliopathy. Acta Neuropathol. 2020;139:947–951. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Lynch DS, Jaunmuktane Z, Sheerin UM, et al. Hereditary leukoencephalopathy with axonal spheroids: A spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series. J Neurol Neurosurg Psychiatr. 2016;87:512–519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Konno T, Yoshida K, Mizuno T, et al. Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation. Eur J Neurol. 2017;24:37–45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Labauge P, Horzinski L, Ayrignac X, et al. Natural history of adult-onset eIF2B-related disorders: A multi-centric survey of 16 cases. Brain. 2009;132:2161–2169. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary material.